Close message

Sodium valproate

By Wikipedia – February 13, 2008
Main article: Valproic acid
Sodium valproate
Systematic (IUPAC) name
sodium 2-propylpentanoate
Identifiers
CAS number 1069-66-5
ATC code N03AG01
PubChem 14047
Chemical data
Formula C8H15NaO2 
Mol. mass 166.20
Pharmacokinetic data
Bioavailability  ?
Protein binding 90-95%
Metabolism 75% by CYP enzymes
Half life 9 -18 hours
Excretion 20% excreted as glucuronide
Therapeutic considerations
Pregnancy cat.

D(AU) D(US)

Legal status

POM(UK) -only(US)

Routes oral, i.v.

Sodium valproate (INN) or valproate sodium (USAN) is the sodium salt of valproic acid and is an anticonvulsant used in the treatment of epilepsy; as well as being used as a mood stabilizer. The intravenous formulations are used when oral administration is not possible.

Contents

Formulations

US

UK & Australia

  • Tablets – Orlept® by Wockhardt and Epilim® by Sanofi-Aventis.
  • Oral solution – Orlept® Sugar Free by Wockhardt and Epilim® by Sanofi-Aventis.
  • Syrup – Epilim® by Sanofi-Aventis.
  • Intravenous injection – Epilim® Intravenous by Sanofi-Aventis.
  • Extended release tablets – Epilim Chrono® by Sanofi-Aventis. A combination of sodium valproate and valproic acid in a 2.3:1 ratio.
  • Enteric-coated tablets – Epilim® EC200 by Sanofi-synthelabo. A 200mg Sodium Valporate enteric-coated tablet.

Germany, Switzerland, Norway

  • Tablets – Orfiril® by Desitin Pharmaceuticals
  • Intravenous injection – Orfiril® IV by Desitin Pharmaceuticals

South Africa

  • Syrup – Convulex® by Byk Madaus

Canada

Others

In much of Europe, Depakine® and Depakine Chrono® are equivalent to Epilim and Epilim Chrono above.

See also

External links

Copyright

The article Sodium valproate was imported from Wikipedia and is licensed under the GNU Free Documentation License.

Rating:
Average: 3.00 out of 1 rating (1 rating)     Log in to rate this Article
Statistics: 27 page views  –   0 comments  –   0 subscriptions
Tags:
Add tags to describe this article

User comments

Post a new comment
  1. There are currently no comments on this article. Be the first to comment.